OakChart

Alaunos Therapeutics Inc

TCRTHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.61-0.10 (-5.85%)
2026-11-12 00:53 CET
Market cap
7.06 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-4.28 USD m
Free cash flow, TTM
-2.83 USD m
EPS diluted, TTM
-1.95
P/E
-
Compare

Price

TCRT against its 20, 50 and 200-day averages
2050200
1.002.003.004.00128.4M256.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TCRTclose 1.6120-day 2.1750-day 1.64200-day 2.281.6152w high52w low

64.2% under the 52-week high of 4.50 on 12 Dec 2025. 52-week low 0.72 on 6 Oct 2026. Last 15 sessions, 103.4% high to low

Volume 0.01× normal · the line is the 50-bar volume average

Profile

TCRT
52-week range, 24% of the way up
0.724.50

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Fort Lauderdale, FL.

Employees1
IPOAug 22, 2005
Beta-1.01
ATR, 14d0.33
Rel volume0.01
Short float5.62%
Insider own20.56%
Inst own22.99%

Snapshot

6 groups

Valuation

Index-
Market Cap6.65M
Enterprise Value6.53M
Income-4.28M
Sales0.00M
Book/sh0.26
Cash/sh0.03
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees1
IPOAug 22, 2005

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B6.14
P/C55.39
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.77
Current Ratio0.77
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.95
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y56.15% 47.89%
Sales past 3/5Y-88.04% -
EPS Y/Y TTM20.95%
Sales Y/Y TTM-50.00%
EPS Q/Q35.20%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.-14.29% -

Ownership

Insider Own20.56%
Insider Trans0.00%
Inst Own22.99%
Inst Trans-0.98%
ROA-128.30%
ROE-185.95%
ROIC-615.03%
Gross Margin-700.00%
Oper. Margin-135266.67%
Profit Margin-142700.00%
SMA20-25.89%
SMA50-2.04%
SMA200-29.52%
Trades-

Technical

Shs Outstand4.13M
Shs Float3.28M
Short Float5.62%
Short Ratio0.02
Short Interest0.18M
52W High4.50 -64.22%
52W Low0.72 123.92%
Volatility8.56% 29.75%
ATR (14)0.33
RSI (14)44.42
Beta-1.01
Rel Volume0.01
Avg Volume7.43M
Volume93,879

Performance

Perf Week-10.56%
Perf Month-46.86%
Perf Quarter-19.10%
Perf Half Y-36.11%
Perf YTD-50.15%
Perf Year-43.11%
Perf 3Y-88.69%
Perf 5Y-99.31%
Perf 10Y-99.84%
Recom2.33
Target Price3.50
Prev Close1.71
Price1.61
Change %-5.85%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Oct 04, 2022ResumedWWells FargoOverweight$3+86.3%

Peers

Mkt cap
TickerCompanyMkt cap
SKYESkye Bioscience Inc4.06M
AARDAardvark Therapeutics Inc34.79M
MTVAMetaVia Inc9.49M
CRBPCorbus Pharmaceuticals Holdings Inc77.36M
LXRXLexicon Pharmaceuticals Inc832.59M
GPCRStructure Therapeutics Inc ADR1.49B
VKTXViking Therapeutics Inc3.63B
SEPNSepterna Inc2.31B
ALTAltimmune Inc375.41M
RYTMRhythm Pharmaceuticals Inc7.78B

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 128

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2023Q32023-11-14-6.000-5.250-6.0000.000.002
2023Q22023-08-14-6.000-6.388-5.4890.000.004
2023Q12023-05-10-6.000-6.345-6.2880.000.005
2022Q42023-03-07-6.000-7.800-6.1500.010.005
2022Q32022-11-14-6.000-7.710-6.1732.910.004
2022Q22022-08-15-7.500-7.200-6.9300.000.005
2022Q12022-05-16-7.500-7.575-6.8310.000.004
2021Q42022-03-30-7.500-12.705-8.2410.000.004
2021Q32021-11-08-16.500-18.855-15.8940.400.007
2021Q22021-08-09-16.500-18.000-15.8580.000.007
2021Q12021-05-06-15.000-15.750-15.1110.000.003
2020Q42021-02-25-16.500-14.820-16.0350.000.00-
2020Q32020-11-05-15.000-13.500-14.3180.000.007
2020Q22020-08-06-13.500-13.710-13.1090.000.007
2020Q12020-05-07-13.500-12.495-13.7330.000.006
2019Q42020-03-02-13.500-11.745-13.1570.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2011FY-145.5-171.75-145.50.670.33
2012FY-183-168.9-1830.800.80
2013FY-99.000-118.88-99.0000.800.90
2014FY-46.500-54.900-46.5001.371.13
2015FY-144-146.12-1444.334.14
2016FY-198-199.59-1986.866.95
2017FY-79.500-80.250-79.5006.396.51
2018FY144-76.765-73.2870.150.33
2019FY-105-104.25-105.210.000.00
2020FY-57.000-55.688-57.2250.000.00
2021FY-0.370-0.394-55.0970.400.40
2022FY-25.500--25.5002.92-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2023Q4S2023-11-221000.000.000.00
2023Q4S2023-11-211000.000.000.00
2023Q4S2023-11-201000.000.000.00
2023Q4S2023-11-191000.000.000.00
2023Q4S2023-11-181000.000.000.00
2023Q4S2023-11-151000.000.000.00
2023Q4S2023-11-141000.000.000.00
2023Q4S2023-11-131000.000.000.00
2023Q4S2023-11-121000.000.000.00
2023Q4S2023-11-111000.000.000.00
2023Q4S2023-11-081000.000.000.00
2023Q4S2023-11-071000.000.000.00
2023Q4S2023-11-061000.000.000.00
2023Q4S2023-11-051000.000.000.00

Estimate history

EPS, annual-79.5-73.287-105.206-57.225-55.097-26.066-21.969-2.922-2.198-1.9481
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.705-0.704-0.463-0.67-0.627-0.55-0.399-0.593-0.406
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual6.3890.146000.3982.9220.0050.010.0050
Period201720182019202020212022202320242025TTM
Sales, quarterly0.00400.0040.002000.00300
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.9511.0741.2121.4311.4411.6031.6011.6012.3492.486
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.6011.6011.6011.6012.0752.2062.3492.3782.486
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.010.010.012.920.400.000.000.15
Cost of Goods Sold Incl. D&A0.020.010.002.312.762.601.130.63-
Gross Profit-0.02-0.000.01-2.310.16-2.20-1.13-0.63-
Selling, General and Administrative Excl. Other4.044.224.8226.1835.4070.9579.2357.2353.48
Research and Development1.651.360.3616.2825.0247.2752.7038.3334.13
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-4.06-4.22-4.81-28.49-35.24-73.15-80.36-57.86-53.91
Interest Expense0.000.000.001.923.151.180.000.000.00
Unusual Expense0.000.030.005.77-0.134.400.0060.75-0.16
Net Income Before Taxes-4.01-4.18-4.68-35.14-37.73-78.75-79.98-117.80-53.12
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-4.01-4.18-4.68-35.14-37.73-78.75-79.98-117.80-53.12
Net Income From Continuing Operations-4.01-4.18-4.68-35.14-37.73-78.75-79.98-117.80-53.12
Net Income-4.28-4.28-4.68-35.14-37.73-78.75-79.98-117.80-70.11
EPS (Recurring)-1.76-2.19-2.92-19.44-26.13-52.94-57.22-67.22-73.40
EPS (Basic, Before Extraordinaries)-1.95-2.20-2.92-21.97-26.07-55.10-57.23-105.21-73.29
EPS (Diluted)-1.95-2.20-2.92-21.97-26.07-55.10-57.23-105.21-73.29
EBITDA-4.03-4.22-4.81-26.18-32.48-70.56-79.23-57.23-53.33
Non-Operating Income (Expense)0.050.080.131.050.53-0.020.390.810.63
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.930.800.432.803.5310.776.836.347.53
Price To Sales Ratio1,831.881,258.64305.043,392.5948.23587.17--1,838.09
Gross Margin-700.00-40.0080.00-46,200.005.58-552.51---
Operating Margin-135,266.67-84,500.00-48,120.00-569,860.00-1,205.95-18,379.90---36,921.92
Net Margin-142,700.00-85,640.00-46,790.00-702,800.00-1,291.24-19,786.68---48,023.97
Shares Outstanding2.492.351.601.601.601.441.431.211.07
Market Capitalization7.067.063.052,551.8523,407.6235,339.8781,002.00128,169.2439,937.59

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.000.00--0.00
Gross Profit-0.01-0.01-0.000.000.00--0.00
Selling, General and Administrative Excl. Other0.941.000.901.191.041.090.761.15
Research and Development0.390.430.360.470.180.35-0.14
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.95-1.01-0.91-1.19-1.04-1.09-0.76-1.15
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.030.000.000.00
Net Income Before Taxes-0.95-1.01-0.89-1.16-1.05-1.07-0.74-1.13
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-0.95-1.01-0.89-1.16-1.05-1.07-0.74-1.13
Net Income From Continuing Operations-0.95-1.01-0.89-1.16-1.05-1.07-0.74-1.13
Net Income-0.99-1.16-0.94-1.20-1.05-1.07-0.74-1.13
EPS (Recurring)-0.41-0.59-0.40-0.55-0.61-0.67-0.46-0.70
EPS (Basic, Before Extraordinaries)-0.41-0.59-0.40-0.55-0.63-0.67-0.46-0.70
EPS (Diluted)-0.41-0.59-0.40-0.55-0.63-0.67-0.46-0.70
EBITDA-0.94-1.00-0.90-1.19-1.04-1.09-0.76-1.15
Non-Operating Income (Expense)0.000.010.010.030.020.020.010.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.250.140.240.300.180.070.080.08
Price To Sales Ratio1,831.881,857.431,517.76876.851,355.05235.38338.93859.34
Gross Margin---133.33-----
Operating Margin---30,233.33---54,600.00-18,875.00-
Net Margin---31,233.33---53,650.00-18,550.00-
Shares Outstanding2.492.382.352.212.071.601.601.60
Market Capitalization7.066.387.215.329.592.353.055.16

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1.391.096.0653.0076.05115.0779.7461.7371.33
Short Term Receivables0.000.010.000.001.114.673.331.860.02
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.601.662.200.801.6710.8622.4220.6919.43
Total Current Assets1.992.758.2653.8078.83130.59105.4984.2890.78
Net Property, Plant & Equipment0.090.000.0010.6015.3614.883.381.101.21
Total Investments and Advances0.000.000.000.000.000.000.000.100.10
Intangible Assets0.000.000.00------
Other Assets0.890.000.000.540.670.880.249.5613.51
Total Assets2.972.758.2664.9494.86146.34109.1195.05105.61
Short Term Debt Incl. Current Port. of LT Debt0.000.000.0017.328.600.820.770.000.00
Accounts Payable0.610.520.621.391.370.960.910.714.42
Other Current Liabilities0.200.181.345.456.0816.5910.858.7816.44
Total Current Liabilities0.810.691.9624.1716.0418.3712.539.4820.86
Long Term Debt0.000.000.002.1920.774.001.580.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.030.000.000.000.0037.56
Total Liabilities0.810.691.9626.3836.8122.3614.109.4958.42
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00143.99
Common Equity2.152.066.3138.5558.06123.9895.0185.56-96.81
Total Shareholders Equity2.152.066.3138.5558.06123.9895.0185.5647.19
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity2.152.066.3138.5558.06123.9895.0185.5647.19
Total Liabilities & Stockholders Equity2.972.758.2664.9494.87146.34109.1195.05105.61
Book Value Per Share0.921.293.9424.0640.2986.6678.3979.69-101.79
Tangible Book Value Per Share0.921.293.9424.0640.2986.6678.3979.69-101.79
Full-Time Employees1113441106734846
Price to Book Ratio6.521.121.224.374.064.369.033.52-7.37
Return on Assets-145.99-84.93-96.01-47.22-65.30-62.61-115.39-52.94-51.26
Return on Equity-198.10-111.80-156.66-78.11-86.52-73.04-130.47-80.03-114.11
Return on Invested Capital-193.96-226.81-557.16-92.60-99.91-62.49-121.96-62.08-115.13
Quick Ratio2.453.984.222.234.917.118.428.894.35
Current Ratio2.453.984.222.234.917.118.428.894.35

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-4.01-4.18-4.68-35.14-37.73-78.75-79.98-117.80-53.12
Depreciation0.020.010.002.315.182.601.130.630.57
Other Funds (Non Cash)0.930.830.438.944.3811.906.8368.097.38
Funds from Operations-3.05-3.34-4.24-23.89-28.17-64.26-72.02-49.08-45.17
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.330.47-0.73-6.25-1.062.7915.018.22-4.29
Cash from Operating Activities-2.73-2.87-4.97-30.14-29.23-61.47-57.01-40.85-49.46
Capital Expenditures-0.10-0.100.00-0.20-0.22-3.32-9.78-0.28-0.46
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.001.540.020.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.10-0.100.001.35-0.19-3.32-9.78-0.28-0.46
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.073.260.000.0914.701.04102.1259.1545.72
Repurchase of Common Pref Stock0.000.000.000.00-0.040.000.00-0.65-1.62
Sale of Common Pref Stock0.073.260.000.0914.741.04102.1259.8047.34
Proceedsfrom Stock Options0.070.000.000.0914.720.00101.686.0847.10
Issuance or Reduction of Debt, Net0.000.000.00-18.11-8.3324.740.000.000.00
Change in Long Term Debt0.000.000.00-18.11-8.3324.740.000.000.00
Issuance of Long Term Debt0.000.000.000.000.0024.740.000.000.00
Reduction of Long Term Debt0.000.000.00-18.11-8.330.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00-5.41
Other Financing Activities Uses0.000.000.000.000.000.000.000.00-5.41
Cash from Financing Activities0.073.260.00-18.146.3725.78102.1259.1540.31
Net Change in Cash-2.750.29-4.97-46.93-23.06-39.0235.3318.01-9.61
Free Cash Flow-2.83-2.97-4.97-30.34-29.45-64.79-66.79-41.14-49.92
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments0.120.351.391.942.880.32
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.540.620.600.750.860.75
Total Current Assets0.670.971.992.693.741.07
Net Property, Plant & Equipment0.070.080.090.100.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.780.830.890.941.001.05
Total Assets1.521.882.973.724.742.12
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.730.400.610.840.810.83
Other Current Liabilities0.130.200.200.080.270.23
Total Current Liabilities0.860.590.810.921.071.06
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.860.590.810.921.071.06
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity0.651.292.152.803.661.06
Total Shareholders Equity0.651.292.152.803.661.06
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity0.651.292.152.803.661.06
Total Liabilities & Stockholders Equity1.521.882.973.724.742.12
Book Value Per Share0.260.540.921.271.760.66
Tangible Book Value Per Share0.260.540.921.271.760.66
Full-Time Employees--1---
Price to Book Ratio6.523.122.541.377.341.14
Return on Assets-128.30-205.30-145.99-110.67-84.84-99.82
Return on Equity-185.95-350.30-198.10-145.65-107.45-139.06
Return on Invested Capital-146.01-78.11-41.48-41.35-28.71-101.42
Quick Ratio0.771.632.452.923.481.00
Current Ratio0.771.632.452.923.481.00

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-0.95-1.01-0.89-1.16-1.05-1.07
Depreciation0.010.010.010.000.000.00
Other Funds (Non Cash)0.250.140.240.300.210.07
Funds from Operations-0.70-0.86-0.64-0.86-0.84-1.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.40-0.170.090.010.140.23
Cash from Operating Activities-0.30-1.03-0.55-0.84-0.70-0.77
Capital Expenditures0.000.00-0.00-0.100.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.00-0.100.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)----0.000.00
Change in Capital Stock0.070.000.000.003.260.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.070.000.000.003.260.00
Proceedsfrom Stock Options0.070.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.070.000.000.003.260.00
Net Change in Cash-0.23-1.03-0.55-0.942.56-0.77
Free Cash Flow-0.30-1.03-0.55-0.94-0.70-0.77

Revenue breakdown

Pharmaceutical Preparations2024: 10.00K 2025: 5.00K
United States2024: 10.00K 2025: 5.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.62%0.2M3.3M7.42M
2026-10-1535.13%0.8M2.3M6.10M
2026-09-300.40%0.0M2.4M787.84K
2026-09-150.29%0.0M2.1M12.44K
2026-08-310.27%0.0M2.1M14.41K
2026-08-140.60%0.0M2.1M15.35K
2026-07-310.49%0.0M2.0M15.33K
2026-07-150.65%0.0M2.0M16.04K
2026-06-300.72%0.0M2.0M16.72K
2026-06-150.57%0.0M2.1M17.12K
2026-05-290.68%0.0M2.0M16.36K
2026-05-150.04%0.0M20.5M14.97K
2026-04-300.44%0.0M2.0M15.73K
2026-04-150.62%0.0M2.0M16.14K
2026-03-310.71%0.0M2.0M20.35K
2026-03-130.72%0.0M1.9M27.91K
2026-02-271.83%0.0M1.9M36.39K
2026-02-132.04%0.0M1.9M43.92K
2026-01-302.38%0.0M1.9M47.75K
2026-01-152.79%0.1M1.9M53.13K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-238-KCurrent report2026-10-22SEC
2026-10-218-KCurrent report2026-10-21SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-13SEC
2026-10-15SCHEDULE 13DSEC
2026-10-15SCHEDULE 13D/ASEC
2026-10-138-KCurrent report2026-10-13SEC
2026-10-098-KCurrent report2026-10-05SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-09-228-KCurrent report2026-09-18SEC
2026-09-21424B3SEC
2026-09-178-KCurrent report2026-09-16SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-06S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-298-KCurrent report2026-06-29SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-05-274Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-268-KCurrent report2026-05-26SEC
2026-05-188-KCurrent report2026-05-18SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-014Statement of changes in beneficial ownership of securities2026-04-29SEC
2026-05-014Statement of changes in beneficial ownership of securities2026-04-29SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.0.87%
GEODE CAPITAL MANAGEMENT, LLC0.66%
VANGUARD FIDUCIARY TRUST CO0.63%
VANGUARD CAPITAL MANAGEMENT LLC0.58%
CITADEL ADVISORS LLC0.49%
OSAIC HOLDINGS, INC.0.07%
Tower Research Capital LLC0.07%
Arax Advisory Partners0.05%
MORGAN STANLEY0.03%
Vanguard Global Advisers, LLC0.02%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.58%
Fidelity Extended Market Index Fund0.48%
Fidelity Total Market Index Fund0.09%
Fidelity Series Total Market Index Fund0.09%
Fidelity Nasdaq Composite Index Fund0.04%

OakChart. TCRT. Cached 15 minutes.

Some panels did not load: insider.